[Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
The combination of L-dopa with carbidopa was administered to 18 patients with ediopathic Parkinson's disease and the dose needed to control the manifestations, either partially or completely, with the least number of side effects, was established.
D000328:Adult; D000368:Aged; D002230:Carbidopa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D013607:Tablets
D004338:Drug Combinations; D006834:Hydrazines; D013607:Tablets; D007980:Levodopa; D002230:Carbidopa
Tratamiento de la enfermedad de Parkinson con levodopa y un inhibidor de la dopadescarvoxilasa